| MINK THERAPEUTICS |
| USA |
| Gesundheit |
| US6036932019 / A40ZAV |
| 6Q40 (Frankfurt) / INKT (NASDAQ) |
| FRA:6Q40, ETR:6Q40, 6Q40:GR, NASDAQ:INKT |
| - |
| https://minktherapeutics... |
|
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The company’s platform is designed to su..
>Volltext.. |
| 47.41 Mio. EUR |
| 39.5 Mio. EUR |
| - |
| -10.96 Mio. EUR |
| -10.2 Mio. EUR |
| -2.15 EUR |
| - |
| 7.91 Mio. EUR |
| -6.13 Mio. EUR |
| 1.16 |
| - |
| -0.76% |
| - |
| - |
| - |
| MINK THERAPEUTICS, MINK THERAPEUTIC |
| 11.11.26 |